Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) Given Average Recommendation of “Hold” by Analysts

Shares of Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) have received a consensus recommendation of “Hold” from the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $27.40.

Several brokerages have recently issued reports on KMTS. Weiss Ratings reissued a “sell (d-)” rating on shares of Kestra Medical Technologies in a research note on Monday, March 23rd. The Goldman Sachs Group lowered their price objective on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research note on Thursday, April 9th. Finally, BTIG Research reissued a “buy” rating and set a $32.00 price objective on shares of Kestra Medical Technologies in a research note on Tuesday, April 7th.

Kestra Medical Technologies Price Performance

Shares of NASDAQ KMTS opened at $18.82 on Friday. Kestra Medical Technologies has a 52-week low of $13.25 and a 52-week high of $30.00. The firm has a fifty day moving average of $20.68 and a 200-day moving average of $23.36. The stock has a market capitalization of $1.10 billion, a PE ratio of -4.75 and a beta of 0.83. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.15.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, March 17th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.01). Kestra Medical Technologies had a negative net margin of 171.87% and a negative return on equity of 65.49%. The company had revenue of $24.55 million for the quarter. Kestra Medical Technologies’s revenue was up 62.7% compared to the same quarter last year. On average, analysts anticipate that Kestra Medical Technologies will post -2.34 EPS for the current year.

Insider Activity

In other news, insider Brian Daniel Webster sold 15,000 shares of the business’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $20.96, for a total transaction of $314,400.00. Following the completion of the sale, the insider directly owned 334,786 shares of the company’s stock, valued at $7,017,114.56. The trade was a 4.29% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have sold 45,000 shares of company stock worth $919,050. 3.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Kestra Medical Technologies

Several hedge funds and other institutional investors have recently made changes to their positions in KMTS. Price T Rowe Associates Inc. MD lifted its holdings in shares of Kestra Medical Technologies by 137.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,369,429 shares of the company’s stock valued at $115,878,000 after acquiring an additional 2,529,851 shares in the last quarter. Franklin Resources Inc. lifted its holdings in shares of Kestra Medical Technologies by 180.8% during the 4th quarter. Franklin Resources Inc. now owns 951,008 shares of the company’s stock valued at $25,221,000 after acquiring an additional 612,343 shares in the last quarter. Millennium Management LLC acquired a new position in shares of Kestra Medical Technologies during the 1st quarter valued at $11,036,000. Brown Advisory Inc. lifted its holdings in shares of Kestra Medical Technologies by 34.1% during the 4th quarter. Brown Advisory Inc. now owns 1,688,356 shares of the company’s stock valued at $44,775,000 after acquiring an additional 428,996 shares in the last quarter. Finally, Summit Partners Public Asset Management LLC acquired a new position in shares of Kestra Medical Technologies during the 4th quarter valued at $9,282,000.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.